Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kenvue

Kimberly-Clark Confirms Kenvue Acquisition Deal: Why It Is Buying the Tylenol Maker

Kimberly-Clark's acquisition of Kenvue marks a major strategic shift as the company expands beyond its traditional personal care and diving deeper into the consumer health market.

International Business Times UK

Amazon Surge Sends S&P 500, Nasdaq Higher to Start November: Stock Market Today

Amazon inked a $38 billion cloud deal with OpenAI, which sent the stock to the top of the Dow Jones on Monday.

Kiplinger

Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity

Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make sense due to the implied expansion of the acquiring entity's product portfolio. However, Kenvue has been ground zero for a controversy involving the flagship over-the-counter…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings

Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Barchart

Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here?

Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares heading into 2026.

Barchart

Kenvue Acquired by Kimberly-Clark in $48.7 Billion Deal to Form Consumer Staples Giant

Kimberly-Clark will acquire Kenvue in a $48.7 billion cash-and-stock deal, creating a new consumer health and personal care giant combining brands like Huggies, Kleenex, Johnson's Baby, and Band-Aid.

International Business Times UK

Stocks See Support From M&A and AI Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.08% the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.55%. December E-mini S&P futures (ESZ25 ) are up +0.16%, and December E-mini Nasdaq futures...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger

Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny

The Guardian - US

Tylenol maker sells to Kimberly Clark for $48B weeks after Trump and RFK Jr targeted drug

The deal announced Monday is among the largest corporate takeovers of the year

The Independent UK

Kimberly-Clark Stock Plunges Over 16%, Kenvue Surges 20% In Monday Pre-Market: What's Going On?

Shares of Kimberly-Clark Corporation (NASDAQ:KMB) plunged 16.15% during the pre-market trading session on Monday, after it announced the acquisition of Kenvue Inc. (NYSE:KVUE) on Monday. Meanwhile Kenvue stock surged 20.04%.

Benzinga

Do Wall Street Analysts Like Kenvue Stock?

Despite Kenvue’s underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations

Patience and a tolerance for risk may be necessary, but these Hold stocks could eventually see big gains, according to analysts.

MarketBeat

Texas Sues Johnson & Johnson for 'Hiding' Tylenol Autism Risks — Billions at Stake in Landmark Case

Texas sues Tylenol's makers over autism risks, echoing Trump-era legal battles over health misinformation with potential billions at stake.

International Business Times UK

Texas sues Tylenol makers alleging deceptive marketing to pregnant people

Lawsuit comes after Trump’s baseless claims that acetaminophen can cause autism and ADHD in children

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading pregnant women about the safety of Tylenol despite evidence suggesting its active ingredient, acetaminophen, may increase the risk of autism and attention disorders in children.

International Business Times UK

Texas Attorney General Targets Tylenol Makers in Controversial Autism Lawsuit

Texas Attorney General Ken Paxton sues Johnson & Johnson and Kenvue, alleging they hid risks linking prenatal Tylenol use to autism and ADHD in children.

The Independent UK

Texas sues Tylenol makers over RFK Jr autism claims saying they failed to state ‘risk of taking drug while pregnant’

State Attorney General Ken Paxton parroted claims by the Health Secretary which have been strongly refuted by medical professionals

The Texas Tribune

Texas attorney general sues Tylenol company over autism claims

This lawsuit comes a month after U.S. Health Secretary Robert F. Kennedy, Jr. updated guidance discouraging pregnant women from taking acetaminophen, citing it as a possible cause of autism.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Dividend Aristocrats So Cheap, Analysts Call Them Buys

These Dividend Aristocrats are trading below the sector average, offer strong yields, and stability.

Barchart

Unusually Active: 4 Options to Watch Next Month for Potential Future Gains

Overall options volume was about average on Thursday, with calls accounting for 60% of the action. Of the 1,291 unusually active options on the day, here are four to watch in the next month.

The Independent UK

Neutrogena makeup remover face wipes recalled in these states over bacteria concerns

More than 1,000 cases of the Neutrogena Makeup Remover Ultra-Soft Cleansing Towelettes have been recalled

Barchart

Kenvue's Quarterly Earnings Preview: What You Need to Know

Kenvue is expected to announce its third-quarter results by early November, and analysts expect a notable decline in earnings.

Barchart

Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Barchart

This Billionaire Investor Is ‘Thrilled’ to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here?

Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy.

International Business Times UK

64-Year-Old Blames Johnson & Johnson for Her Ovarian Cancer — Joins 3,000 Suing the Pharma Giant

UK's first talc cancer group claim accuses Johnson & Johnson and Kenvue of failing to warn about asbestos risk — £1 billion suit backed by 3,000 claimants.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.